Randomised clinical trial: Rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 5, 2011, Pages 519-525

  Luo, J C ^a,b   Huang, K W ^a,b   Leu, H B ^a,b   Chen, L C ^b,c   Hou, M C ^a,b   Li, C P ^a,b   Lu, C L ^a,b   Lin, H C ^a,b   Lee, F Y ^a,b   Lee, S D ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PLATELET AGGREGATION INHIBITORS; REGRESSION ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79961211335     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04760.x     Document Type: Article

References (30)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2. Awtry EH, Loscalzo J,. Aspirin. Circulation 2000; 101: 1206-18. (Pubitemid 30146625)
3. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of anti-platelet agents. Eur Heart J 2004; 25: 166-81.
4. Luo JC,. Gastro-protective strategy in aspirin users. J Chin Med Assoc 2009; 72: 343-5.
5. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-86. (Pubitemid 34407526)
6. Luk HH,. Use of gastro-protective drugs in patients receiving low-dose aspirin. J Chin Med Assoc 2009; 72: 356-61.
7. Liberopoulos EN, Elisaf M, Tselepis AD, et al. Upper gastrointestinal hemorrhage complicating anti-platelet treatment with aspirin and/or clopidogrel: where we are now? Platelets 2006; 17: 1-6. (Pubitemid 41759234)
8. Fork FT, Lafolie P, Toth E, Lindgarde F,. Gastrointestinal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. Scand J Gastroenterol 2000; 25: 464-9. (Pubitemid 30354084)
9. Chan FKL, Ching JYL, Hung LCT, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. New Engl J Med 2005; 352: 238-44. (Pubitemid 40110812)
10. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4: 860-5.
11. Cryer B, Feldman M,. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25. (Pubitemid 29297615)
12. Luo JC, Shin VY, Liu ESL, et al. Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. J Pharmacol Exp Ther 2003; 307: 692-8. (Pubitemid 37310685)
13. Sibilia V, Pagani F, Lattuada N, et al. Ticlopidine prevents the formation but delays the healing of ethanol-induced gastric lesions in rats. Pharmacol Res 2007; 55: 418-25. (Pubitemid 46560394)
14. Ma L, Elliott SN, Girino G, et al. Platelets modulate gastric ulcer healing. Role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 2001; 98: 6470-5. (Pubitemid 32488261)
15. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the anti-platelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
16. Hsu PI, Lai KH, Liu CP,. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011; 140: 791-8.
17. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. New Engl J Med 2010; 363: 1909-17.
18. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 1998; 12: 135-40.
19. Hsiang KW, Ng YY, Lu CL, et al. Corticosteroids therapy and peptic ulcer disease in nephrotic syndrome patients. Br J Clin Pharmacol 2010; 70: 756-61.
20. Luo JC, Lin HY, Chang FY, et al. Occurrence of peptic ulcer disease in connective tissue disease patients associated with xerostomia. Aliment Pharmacol Ther 2003; 17: 217-24.
21. Ng FH, Wong BCY, Wong SY, Chen WH, Chang CM,. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk, a single-blinded, randomized controlled study. Aliment Pharmacol Ther 2004; 19: 359-65.
22. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 2009; 374: 989-97.
23. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastro-duodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801. (Pubitemid 41564359)
24. Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs. ranitidine in healing non-steroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multi-center study. NSAID-Associated Gastric Ulcer Study Group. Arch Int Med 2000; 160: 1455-61. (Pubitemid 30327448)
25. Simon WA, Sturm E, Hartmann HJ, Weser U,. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol 2006; 71: 1337-41.
26. Ng KM, Cho CH, Chang FY, et al. Omeprazole promotes gastric epithelial cell migration. J Pharm Pharmacol 2008; 60: 655-60.
27. Jaworski T, Sarosiek I, Sostarich S, et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci 2005; 50: 357-65. (Pubitemid 40311548)
28. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmaco-genetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
29. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352: 1016-21. (Pubitemid 28438573)
30. Chan FK, Hawkey CJ, Lanas AI,. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: a three-way debate. Am J Med 2001; 110: 55S-7S. (Pubitemid 32144905)